Clinical Trials Logo
  1. Home
  2. Stage IV Lung Cancer
  3. NCT03112668

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Stage IV Breast Cancer Clinical Trial

Official title:
Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study

Clinical Trial Summary

This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners. Learning how to accept negative thoughts and feelings and how to live in the present without worrying about the future or past may improve coping skills in patients with stage III-IV cancer and their partners.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To examine the feasibility and acceptability of couples' acceptance and commitment therapy (ACT) (C-ACT). II. To collect pilot data on the impact of C-ACT on patients' and partners' anxiety, depression, and quality of life. OUTLINE: Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session. After completion of the study, patients and their partners are followed up at 1 week. ;

Study Design

Related Conditions & MeSH terms

  • Breast Neoplasms
  • Carcinoma
  • Colorectal Neoplasms
  • Genital Neoplasms, Female
  • Lung Neoplasms
  • Malignant Female Reproductive System Neoplasm
  • Malignant Hepatobiliary Neoplasm
  • Melanoma
  • Neoplasms
  • Partner
  • Prostatic Neoplasms
  • Skin Neoplasms
  • Stage III Breast Cancer
  • Stage III Cervical Cancer
  • Stage III Colorectal Cancer
  • Stage III Lung Cancer
  • Stage III Prostate Cancer
  • Stage III Skin Melanoma
  • Stage III Uterine Corpus Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIA Cervical Cancer
  • Stage IIIA Colorectal Cancer
  • Stage IIIA Lung Carcinoma
  • Stage IIIA Skin Melanoma
  • Stage IIIA Uterine Corpus Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIB Cervical Cancer
  • Stage IIIB Colorectal Cancer
  • Stage IIIB Lung Carcinoma
  • Stage IIIB Skin Melanoma
  • Stage IIIB Uterine Corpus Cancer
  • Stage IIIC Breast Cancer
  • Stage IIIC Colorectal Cancer
  • Stage IIIC Skin Melanoma
  • Stage IIIC Uterine Corpus Cancer
  • Stage IV Breast Cancer
  • Stage IV Cervical Cancer
  • Stage IV Colorectal Cancer
  • Stage IV Lung Cancer
  • Stage IV Prostate Cancer
  • Stage IV Skin Melanoma
  • Stage IV Uterine Corpus Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Colorectal Cancer
  • Stage IVA Uterine Corpus Cancer
  • Stage IVB Cervical Cancer
  • Stage IVB Colorectal Cancer
  • Stage IVB Uterine Corpus Cancer
  • Uterine Cervical Neoplasms
Clinical Trial Details
NCT number NCT03112668
Study type Interventional
Source Rutgers, The State University of New Jersey
Contact
Status Completed
Phase N/A
Start date December 6, 2017
Completion date January 25, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01987726 - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Terminated NCT01918306 - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Phase 1/Phase 2
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00602043 - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Phase 2
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00100750 - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT00096109 - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase 2
Completed NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer Phase 2
Completed NCT00057941 - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Phase 2
Terminated NCT02892734 - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Phase 2
Recruiting NCT03213041 - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Phase 2
Completed NCT02015559 - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus Phase 2
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01672684 - Phase I: At-Home Support for Rural Women Using Group Video Calling Phase 1
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1